000			02315 a2200685 4500
005			20250517044740.0
264		0	_c20160412
008			201604s 0 0 eng d
022			_a2041-4889
024	7		_a10.1038/cddis.2015.217 _2doi
040			_aNLM _beng _cNLM
100	1		_aSette, G
245	0	0	_aTyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. _h[electronic resource]
260			_bCell death & disease _cAug 2015
300			_ae1850 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xdrug therapy
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBiomarkers, Pharmacological _xmetabolism
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aCarcinoma, Squamous Cell _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aErbB Receptors _xgenetics
650	0	4	_aErlotinib Hydrochloride _xpharmacology
650	0	4	_aFemale
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, SCID
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Staging
650	0	4	_aNeoplastic Stem Cells _xdrug effects
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProtein Kinase Inhibitors _xpharmacology
650	0	4	_aProto-Oncogene Proteins p21(ras) _xgenetics
650	0	4	_aReceptor, ErbB-2 _xgenetics
650	0	4	_aSignal Transduction
650	0	4	_aTyrosine _xmetabolism
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aSalvati, V
700	1		_aMottolese, M
700	1		_aVisca, P
700	1		_aGallo, E
700	1		_aFecchi, K
700	1		_aPilozzi, E
700	1		_aDuranti, E
700	1		_aPolicicchio, E
700	1		_aTartaglia, M
700	1		_aMilella, M
700	1		_aDe Maria, R
700	1		_aEramo, A
773	0		_tCell death & disease _gvol. 6 _gp. e1850
856	4	0	_uhttps://doi.org/10.1038/cddis.2015.217 _zAvailable from publisher's website
999			_c25144411 _d25144411